Infrastructure name
StemBANCC (FP7-IMI-Seventh Framework Programme/Innovative Medicines Initiative)
Institute/location
Key contact
Contact phone number
Contact email
Project/infrastructure description
Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC)
Date funding committed
01/10/2012
Date infrastructure operational
Total capital cost (Euros)
26,000,000
Does the 'Total Capital Cost' include other associated costs?
Current infrastructure status
Is this entry applicable to another section of this questionnaire?
Further information available at:
The aim of the STEMBANCC project is to generate and characterise 1 500 high quality human induced pluripotent stem (iPS) cell lines that can be used by researchers to study a range of diseases, including diabetes and dementia, and test for drug efficacy and safety. The cell lines will help to improve and speed up the drug development process, and ensure that patients benefit from more effective and safer drugs. Stem cells, iPSC, diabetes, neurological, toxicology, assay development, biobank
Types: Capital Infrastructure
Member States: European Commission
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A